When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARDS - Aridis Pharma on go with mid-stage study of AR-501 in cystic fibrosis
Aridis Pharmaceuticals Inc.
Aridis Pharmaceuticals (NASDAQ:ARDS) has reached an agreement with the FDA to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF).
More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news,